<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="39689"><DrugName>cobiprostone</DrugName><DrugNamesKey><Name id="42871613">cobiprostone</Name></DrugNamesKey><DrugSynonyms><Name><Value>RU-8811</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cobiprostone</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>SPI-8811</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>333963-42-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29221">Sucampo Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="29221">Sucampo Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="39689" type="Drug"><TargetEntity id="325208" type="siDrug">Cobiprostone</TargetEntity></SourceEntity><SourceEntity id="29221" type="Company"><TargetEntity id="4295900124" type="organizationId">Sucampo Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"/><TargetEntity id="D029424" type="MeSH"/><TargetEntity id="-459670493" type="omicsDisease"/><TargetEntity id="277" type="siCondition"/></SourceEntity><SourceEntity id="1243" type="ciIndication"><TargetEntity id="K21" type="ICD10"/><TargetEntity id="530.81" type="ICD9"/><TargetEntity id="10017885" type="MEDDRA"/><TargetEntity id="D005764" type="MeSH"/><TargetEntity id="-837084427" type="omicsDisease"/><TargetEntity id="389" type="siCondition"/></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"/><TargetEntity id="D008107" type="MeSH"/><TargetEntity id="-35813413" type="omicsDisease"/><TargetEntity id="415" type="siCondition"/></SourceEntity><SourceEntity id="2637" type="ciIndication"><TargetEntity id="K75.81" type="ICD10"/><TargetEntity id="1412" type="siCondition"/></SourceEntity><SourceEntity id="3239" type="ciIndication"><TargetEntity id="K76.6" type="ICD10"/><TargetEntity id="10036200" type="MEDDRA"/><TargetEntity id="D006975" type="MeSH"/><TargetEntity id="-1694342153" type="omicsDisease"/><TargetEntity id="242" type="siCondition"/></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"/></SourceEntity><SourceEntity id="478" type="ciIndication"><TargetEntity id="I73.0" type="ICD10"/><TargetEntity id="10037912" type="MEDDRA"/><TargetEntity id="D011928" type="MeSH"/><TargetEntity id="-140562337" type="omicsDisease"/><TargetEntity id="263" type="siCondition"/></SourceEntity><SourceEntity id="805" type="ciIndication"><TargetEntity id="K25" type="ICD10"/><TargetEntity id="10017822" type="MEDDRA"/><TargetEntity id="D013276" type="MeSH"/><TargetEntity id="-1478965724" type="omicsDisease"/><TargetEntity id="410" type="siCondition"/></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"/><TargetEntity id="10011762" type="MEDDRA"/><TargetEntity id="D003550" type="MeSH"/><TargetEntity id="586" type="ORPHANET"/><TargetEntity id="-1447400656" type="omicsDisease"/><TargetEntity id="288" type="siCondition"/></SourceEntity><SourceEntity id="776" type="Action"><TargetEntity id="1290" type="Mechanism">Chloride Channel Activators</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1185">Chronic obstructive pulmonary disease</Indication><Indication id="1243">Gastroesophageal reflux</Indication><Indication id="189">Inflammatory bowel disease</Indication><Indication id="201">Liver disease</Indication><Indication id="2637">Non-alcoholic steatohepatitis</Indication><Indication id="3209">Oral mucositis</Indication><Indication id="3239">Portal hypertension</Indication><Indication id="347">Wound healing</Indication><Indication id="478">Raynauds disease</Indication><Indication id="805">Stomach ulcer</Indication><Indication id="88">Cystic fibrosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="776">Chloride channel stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action><Action id="2953">Anti-inflammatory</Action><Action id="388">Vasodilator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>A2B</Code><Name>ANTIULCERANTS</Name></Ephmra><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-20T17:06:20.000Z</LastModificationDate><ChangeDateLast>2016-07-15T00:00:00.000Z</ChangeDateLast><AddedDate>2002-05-14T09:21:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29221" linkType="Company"&gt;Sucampo Pharmaceuticals&lt;/ulink&gt; was developing cobiprostone (SPI-8811; RU-8811), a functional fatty acid compound and locally acting chloride-channel activator  for the potential treatment of cystic fibrosis (CF) and oral mucositis  [&lt;ulink linkID="450286" linkType="reference"&gt;450286&lt;/ulink&gt;], [&lt;ulink linkID="450934" linkType="reference"&gt;450934&lt;/ulink&gt;], [&lt;ulink linkID="832094" linkType="Reference"&gt;832094&lt;/ulink&gt;], [&lt;ulink linkID="1339083" linkType="Reference"&gt;1339083&lt;/ulink&gt;], [&lt;ulink linkID="1657272" linkType="Reference"&gt;1657272&lt;/ulink&gt;]. The company was also investigating the drug for the potential treatment of COPD, inflammatory bowel  disease (IBD) and wound healing   [&lt;ulink linkID="1082316" linkType="Reference"&gt;1082316&lt;/ulink&gt;], [&lt;ulink linkID="1322608" linkType="Reference"&gt;1322608&lt;/ulink&gt;], [&lt;ulink linkID="1327329" linkType="Reference"&gt;1327329&lt;/ulink&gt;], [&lt;ulink linkID="1328555" linkType="Reference"&gt;1328555&lt;/ulink&gt;]. However, in July 2016, Sucampo  discontinued development of cobiprostone following a prespecified futility analysis of a phase IIa study in oral mucositis indicating that the clinical benefit was insufficient to support  study  continuation [&lt;ulink linkID="1779305" linkType="Reference"&gt;1779305&lt;/ulink&gt;].        &lt;/para&gt;&lt;para&gt;By January 2009, two phase II trials for CF had been completed [&lt;ulink linkID="975238" linkType="Reference"&gt;975238&lt;/ulink&gt;]; in October 2012, the drug was listed as being in phase II development for CF [&lt;ulink linkID="1327329" linkType="Reference"&gt;1327329&lt;/ulink&gt;]. In June 2015, a phase II trial in oral mucositis was initiated in the US [&lt;ulink linkID="1693538" linkType="Reference"&gt;1693538&lt;/ulink&gt;]. In October 2012, the drug was listed as being in preclinical development for IBD, COPD, wound healing [&lt;ulink linkID="1327329" linkType="Reference"&gt;1327329&lt;/ulink&gt;]. In July 2009, the company was seeking to outlicense the drug for commercialization [&lt;ulink linkID="1022876" linkType="Reference"&gt;1022876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sucampo was also previously developing the drug for the potential treatment of liver disease, portal hypertension, the potential prevention of ulcers and gastrointestinal injuries in NSAID-treated arthritis patients, and non-erosive reflux disease [&lt;ulink linkID="450286" linkType="reference"&gt;450286&lt;/ulink&gt;], [&lt;ulink linkID="450934" linkType="reference"&gt;450934&lt;/ulink&gt;], [&lt;ulink linkID="832094" linkType="Reference"&gt;832094&lt;/ulink&gt;]. In July 2009, positive data from a phase II trial for the prevention of NSAID-induced gastric ulcers in arthritis patients were reported [&lt;ulink linkID="832094" linkType="Reference"&gt;832094&lt;/ulink&gt;], [&lt;ulink linkID="1022876" linkType="Reference"&gt;1022876&lt;/ulink&gt;]. By January 2009, two phase I trials  and phase II trials for Raynaud's disease, non-alcoholic fatty liver disease had been completed [&lt;ulink linkID="975238" linkType="Reference"&gt;975238&lt;/ulink&gt;].  In July 2008, a phase II trial for  portal hypertension in patients with liver cirrhosis began [&lt;ulink linkID="928792" linkType="Reference"&gt;928792&lt;/ulink&gt;]. In March 2010, the design of a phase IIb trial for NSAID-induced gastrointestinal injury was ongoing [&lt;ulink linkID="1082316" linkType="Reference"&gt;1082316&lt;/ulink&gt;]; however, no further development was reported for ulcers, gastrointestinal injuries, Raynaud's disease, non-alcoholic fatty liver disease and portal hypertension since March 2012. In February 2015, the first patient was dosed in a phase II  trial  for non-erosive reflux disease in proton pump inhibitor-refractory patients [&lt;ulink linkID="1657272" linkType="Reference"&gt;1657272&lt;/ulink&gt;]; in April 2016, topline data from the trial were reported [&lt;ulink linkID="1753230" linkType="Reference"&gt;1753230&lt;/ulink&gt;]. In April 2016, the company discontinued the development of cobiprostone for PPI-refractory NERD/sGERD because the drug had not achieved endpoints in the phase IIa trial [&lt;ulink linkID="1753230" linkType="Reference"&gt;1753230&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2015, the FDA granted Fast Track status to cobiprostone for the prevention of oral mucositis [&lt;ulink linkID="1657906" linkType="Reference"&gt;1657906&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, cobiprostone received orphan drug status for CF [&lt;ulink linkID="505882" linkType="reference"&gt;505882&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Portal hypertension&lt;/subtitle&gt;In July 2008, the company began enrollment in a US phase II trial for  portal hypertension in patients with liver cirrhosis. The 30-patient, single-center, double-blind, randomized, placebo-controlled study would assess cobiprostone's safety and efficacy. The primary endpoint was the change from baseline in hepatic venous pressure gradient (HVPG) after 28 days of treatment. Secondary endpoints included acute changes in HVPG following initial cobiprostone dosing, quality of life and other markers of liver disease [&lt;ulink linkID="928792" linkType="Reference"&gt;928792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of NSAID-induced ulcers&lt;/subtitle&gt;In September 2007, Sucampo initiated a double-blind, randomized, placebo-controlled, US phase II trial for the prevention of NSAID-induced gastric ulcers in arthritis patients. The study would enroll 120 subjects and the primary endpoint would be the overall incidence of ulcers during the study period. Secondary endpoints would include the incidence of duodenal ulcers, the change in the number of ulcers and/or erosions, time-to-onset analysis of ulcer development and severity of overall gastrointestinal injury [&lt;ulink linkID="832094" linkType="Reference"&gt;832094&lt;/ulink&gt;]. In January 2009, enrollment in the study of 124 patients was completed. The trial would assess  18 microg of the drug administered qd, bid and tid, with all patients receiving 500 mg of naproxen bid [&lt;ulink linkID="975238" linkType="Reference"&gt;975238&lt;/ulink&gt;]. In May 2009, efficacy data would be reported in mid-2009 [&lt;ulink linkID="1007551" linkType="Reference"&gt;1007551&lt;/ulink&gt;]. In July 2009, topline efficacy data from the 12-week study were reported. Subjects treated with cobiprostone experienced a lower overall incidence of ulcers, with 50% reduction at the highest drug dose level (54 microg). The drug significantly reduced the number of gastric erosions in a dose-dependent manner, and delayed the time-to-onset of all ulcer or erosion development. Subjects who received naproxen with cobiprostone showed increased retention rates than subjects treated with naproxen and placebo. The drug was well tolerated with the most common adverse events being diarrhea, nausea and gastritis [&lt;ulink linkID="1022876" linkType="Reference"&gt;1022876&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cystic fibrosis&lt;/subtitle&gt;In September 2003, a multicenter phase IIa study began in 24 to 30 patients with documented CF, randomized into three, open-label, dose-escalating cohorts at four US sites. At least eight subjects were to complete dosing in each cohort [&lt;ulink linkID="505882" linkType="reference"&gt;505882&lt;/ulink&gt;]. By January 2009, two phase I trials  and phase II trials for CF had been completed [&lt;ulink linkID="975238" linkType="Reference"&gt;975238&lt;/ulink&gt;]. In October 2012, the drug was in phase II development for CF [&lt;ulink linkID="1327329" linkType="Reference"&gt;1327329&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver disease&lt;/subtitle&gt;In April 2002, the compound was undergoing clinical development for liver disease. In September 2002, Sucampo began a phase II study in the US in approximately 20 patients with non-alcoholic steatohepatitis [&lt;ulink linkID="464970" linkType="reference"&gt;464970&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Oral mucositis&lt;/subtitle&gt;In May 2014, a phase IIa study for oral mucositis was planned to begin in the second half of 2014 [&lt;ulink linkID="1554382" linkType="Reference"&gt;1554382&lt;/ulink&gt;]. In March 2015, the company  filed an IND application for cobiprostone to initiate a phase IIa  trial in patients suffering from head and neck cancer for the treatment of oral mucositis. The  trial was expected to begin at the end of the first half of 2015 [&lt;ulink linkID="1657272" linkType="Reference"&gt;1657272&lt;/ulink&gt;]. In May 2015, the IND was accepted by the FDA and the trial was expected to be initiated by the end of that quarter [&lt;ulink linkID="1657906" linkType="Reference"&gt;1657906&lt;/ulink&gt;]. In June 2015, the double-blind, randomized, parallel-assigned, placebo-controlled, phase II trial (&lt;ulink linkID="239657" linkType="Protocol"&gt;NCT02542215&lt;/ulink&gt;; SCMP-8811-202) to evaluate the safety and efficacy of cobiprostone in subjects (expected n = ) with head and neck cancer for the prevention of oral mucositis was initiated in the US. At that time, the trial was expected to complete in December 2016 [&lt;ulink linkID="1693538" linkType="Reference"&gt;1693538&lt;/ulink&gt;]. In May 2016,  a futility analysis on the trial was expected  in the second half of that year [&lt;ulink linkID="1759024" linkType="Reference"&gt;1759024&lt;/ulink&gt;]. In July 2016, data from a prespecified futility analysis indicating that the clinical benefit was insufficient to support  study  continuation were reported and the study was terminated. The drug was well-tolerated with a safety profile consistent with  that noted in phase I studies, and no safety concerns were identified  [&lt;ulink linkID="1779305" linkType="Reference"&gt;1779305&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May 2013, the company planned to initiate next trial in the fourth quarter of 2013 [&lt;ulink linkID="1416803" linkType="Reference"&gt;1416803&lt;/ulink&gt;]. in August 2013,  a phase Ib study was expected to begin in the fourth quarter of 2013   [&lt;ulink linkID="1463249" linkType="Reference"&gt;1463249&lt;/ulink&gt;]; in October 2013, the trial was initiated [&lt;ulink linkID="1496794" linkType="Reference"&gt;1496794&lt;/ulink&gt;]. By May 2014, data had been reported from the safety and pharmacokinetic study. The drug was well tolerated with low systemic exposure [&lt;ulink linkID="1554382" linkType="Reference"&gt;1554382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2012, a phase I study for oral mucositis in healthy Japanese subjects had been initiated. At that time, the study was expected to complete in the first quarter of 2013 [&lt;ulink linkID="1339083" linkType="Reference"&gt;1339083&lt;/ulink&gt;]. In March 2013, the study was expected to be completed in the second quarter of 2013 [&lt;ulink linkID="1391936" linkType="Reference"&gt;1391936&lt;/ulink&gt;]. By March 2013, the trial had been completed and the results were expected in the second quarter of 2013 [&lt;ulink linkID="1416803" linkType="Reference"&gt;1416803&lt;/ulink&gt;]. In August 2013, results were reported from the single-center, placebo-controlled, randomized, double-blind study which assessed an oral spray formulation of the drug in 48 healthy subjects. No severe adverse events occurred. The most common adverse event was mild diarrhea [&lt;ulink linkID="1463249" linkType="Reference"&gt;1463249&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-erosive reflux disease&lt;/subtitle&gt;In February 2015, the first patient was dosed in a phase II  trial  for non-erosive reflux disease in proton pump inhibitor-refractory patients [&lt;ulink linkID="1657272" linkType="Reference"&gt;1657272&lt;/ulink&gt;]. In April 2016, top-line data from the randomized, double-blind, placebo-controlled, multicenter, phase IIa trial that evaluated the safety and efficacy of cobiprostone in 153 refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD) patients were reported. Data demonstrated that cobiprostone did not meaningfully improve heartburn symptoms as determined by patient reported outcomes, the primary endpoint of the study but showed significant benefit in some of the secondary measures. The drug was safe and well-tolerated. At that time, the company discontinued the development of cobiprostone for PPI-refractory NERD/sGERD [&lt;ulink linkID="1753230" linkType="Reference"&gt;1753230&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2012, the drug was being investigated for the potential treatment of inflammatory bowel disease [&lt;ulink linkID="1322608" linkType="Reference"&gt;1322608&lt;/ulink&gt;}. In May 2012, preclinical data on the ability of cobiprostone to protect the gastric epithelial barrier against exposure to indomethacin were presented at Digestive Disease Week 2012, in San Diego, CA. Cobiprostone pretreatment of MKN28 gastric epithelial monolayers significantly attenuated indomethacin-induced transepithelial electrical resistance and paracellular permeability (p &amp;lt; 0.05) [&lt;ulink linkID="1291790" linkType="Reference"&gt;1291790&lt;/ulink&gt;], [&lt;ulink linkID="1292815" linkType="Reference"&gt;1292815&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2008, data from a hepatic cirrhosis model had shown cobiprostone to decrease portal vein pressure and reduce vascular resistance in the liver in an ex vivo model [&lt;ulink linkID="928792" linkType="Reference"&gt;928792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data showing the efficacy of cobiprostone against naproxen-induced gastric ulcers in rats and acid-induced mucosal injury in porcine gastric mucosa were reported in May 2008 at the DDW meeting in San Diego, CA [&lt;ulink linkID="906918" linkType="Reference"&gt;906918&lt;/ulink&gt;], [&lt;ulink linkID="911447" linkType="Reference"&gt;911447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data were presented at the American College of Gastroenterology Annual Scientific Meeting in Philadelphia. The in vitro study data showed that cobiprostone was able to reduce cellular death and promote the regrowth of human intestinal T84 cells damaged by indomethacin (an NSAID). The data also showed that cobiprostone prevented indomethacin-induced increases in both calcium ions and mitochondrial dysfunction [&lt;ulink linkID="839215" linkType="Reference"&gt;839215&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1243">Gastroesophageal reflux</Indication><StatusDate>2016-04-19T00:00:00.000Z</StatusDate><Source id="1753230" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="347">Wound healing</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="88">Cystic fibrosis</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3209">Oral mucositis</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3209">Oral mucositis</Indication><StatusDate>2016-07-11T00:00:00.000Z</StatusDate><Source id="1779305" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="805">Stomach ulcer</Indication><StatusDate>2009-03-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate>2010-06-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3239">Portal hypertension</Indication><StatusDate>2010-01-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate>2010-06-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2637">Non-alcoholic steatohepatitis</Indication><StatusDate>2002-09-24T00:00:00.000Z</StatusDate><Source id="464970" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3239">Portal hypertension</Indication><StatusDate>2008-07-28T00:00:00.000Z</StatusDate><Source id="928792" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="805">Stomach ulcer</Indication><StatusDate>2007-09-20T00:00:00.000Z</StatusDate><Source id="832094" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="478">Raynauds disease</Indication><StatusDate>2009-01-08T00:00:00.000Z</StatusDate><Source id="975238" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3209">Oral mucositis</Indication><StatusDate>2011-04-12T00:00:00.000Z</StatusDate><Source id="1328555" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1243">Gastroesophageal reflux</Indication><StatusDate>2015-02-28T00:00:00.000Z</StatusDate><Source id="1657272" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3209">Oral mucositis</Indication><StatusDate>2012-09-30T00:00:00.000Z</StatusDate><Source id="1339083" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3209">Oral mucositis</Indication><StatusDate>2015-06-30T00:00:00.000Z</StatusDate><Source id="1693538" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2003-09-04T00:00:00.000Z</StatusDate><Source id="503968" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2012-03-31T00:00:00.000Z</StatusDate><Source id="1322608" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>2010-03-15T00:00:00.000Z</StatusDate><Source id="1082316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1185">Chronic obstructive pulmonary disease</Indication><StatusDate>2010-03-15T00:00:00.000Z</StatusDate><Source id="1082316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29221">Sucampo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="201">Liver disease</Indication><StatusDate>2002-05-03T00:00:00.000Z</StatusDate><Source id="450934" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="29221">Sucampo Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3209">Oral mucositis</Indication><AwardedIndication>Prevention of oral mucositis</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-05-07T00:00:00.000Z</MileStoneDate><Source id="1657906" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29221">Sucampo Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="88">Cystic fibrosis</Indication><AwardedIndication>Treatment of cystic fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2002-11-14T00:00:00.000Z</MileStoneDate><Source id="505882" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00447"><Name>Chloride channel</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC[C@H](C)CC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1318359" number="WO-2007086536" title="Soft-gelatin capsule formulation"/><PatentFamily id="2027629" number="WO-00220007" title="Cathartic composition."/><PatentFamily id="2270725" number="WO-2005002588" title="Enteric coated composition comprising prostaglandin analogs as chloride channel opener"/><PatentFamily id="2382964" number="WO-2012144649" title="Method for modulating cytokine activity"/><PatentFamily id="2388660" number="WO-2012148002" title="Method for modulating ion transporter"/><PatentFamily id="2846664" number="WO-2014200117" title="Method for suppressing tumorigenicity of stem cells"/><PatentFamily id="346086" number="WO-00127099" title="Novel composition and method for stabilizing the same"/><PatentFamily id="3481833" number="WO-2016203317" title="Pharmaceutical compositions comprising fatty acid derivative"/><PatentFamily id="446000" number="WO-2011002100" title="Medicament for the long term NSAID use"/><PatentFamily id="848483" number="WO-2007102446" title="Method and composition for treating chronic obstructive pulmonary disease"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harbin Gloria Pharmaceuticals Co Ltd" id="1065561"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mallinckrodt plc" id="1085756"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Endo International plc" id="1089706"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="S&amp;R Foundation" id="1107931"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson Matthey plc" id="17609"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cincinnati" id="20555"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>